Regeneron Appeals After Judge Declines to Block Amgen Biosimilar

Regeneron Pharmaceuticals Inc. quickly appealed a judge’s order declining to block Amgen Inc.'s biosimilar version of its blockbuster eye drug Eylea while a patent-infringement suit continues.

Judge Thomas S. Kleeh issued an order under seal Monday denying Regeneron’s motion for a preliminary injunction in the US District Court for the Northern District of West Virginia. Regeneron filed a notice later Monday that it’s appealing that order to the US Court of Appeals for the Federal Circuit.

Regeneron—which attributed nearly 44% of its 2023 revenue to Eylea’s US sales—in mid-June won preliminary injunctions blocking two other biosimilars: Samsung Bioepis Co.'s Opuviz ...